Finland is taking an important step forward in clinical research by accelerating timelines for nationally focused clinical trial applications — including a 30 day assessment period that begins at submission, not after validation.
This shift enables faster study start up, smoother coordination with authorities, and a more predictable pathway for sponsors. Read more at Fimea.
At Aurevia, we help companies navigate the regulatory landscape and provide expert support with clinical operations and submissions. Let our team help you streamline your clinical study start-up and enable you to achieve success.
